

CYP3A4 Antibody

Mouse Monoclonal Antibody (Mab) Catalog # AM2065a

Product Information

Application	WB, E
Primary Accession	<u>P08684</u>
Other Accession	<u>NP_059488.2</u>
Reactivity	Human
Host	Mouse
Clonality	Monoclonal
Isotype	IgM
Clone Names	501CT16.1.1
Calculated MW	57343
Antigen Region	228-255

Additional Information

Gene ID	1576
Other Names	Cytochrome P450 3A4, 11413-, 8-cineole 2-exo-monooxygenase, Albendazole monooxygenase, Albendazole sulfoxidase, CYPIIIA3, CYPIIIA4, Cytochrome P450 3A3, Cytochrome P450 HLp, Cytochrome P450 NF-25, Cytochrome P450-PCN1, Nifedipine oxidase, Quinine 3-monooxygenase, Taurochenodeoxycholate 6-alpha-hydroxylase, CYP3A4, CYP3A3
Target/Specificity	This CYP3A4 antibody is generated from mice immunized with a KLH conjugated synthetic peptide between 228-255 amino acids from human CYP3A4.
Dilution	WB~~1:100~1000 E~~Use at an assay dependent concentration.
Format	Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Euglobin precipitation followed by dialysis against PBS.
Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	CYP3A4 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

ne

CYP3A4 {ECO:0000303|PubMed:11470997, ECO:0000312|HGNC:HGNC:2637}

Function	A cytochrome P450 monooxygenase involved in the metabolism of sterols, steroid hormones, retinoids and fatty acids (PubMed: <u>10681376</u> , PubMed: <u>11093772</u> , PubMed: <u>11555828</u> , PubMed: <u>12865317</u> , PubMed: <u>14559847</u> , PubMed: <u>15373842</u> , PubMed: <u>15764715</u> ,
	PubMed: <u>19965576</u> , PubMed: <u>20702771</u> , PubMed: <u>21490593</u> , PubMed: <u>21576599</u>). Mechanistically, uses molecular oxygen inserting one
	oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPHhemoprotein reductase). Catalyzes the hydroxylation of
	carbon-hydrogen bonds (PubMed: <u>12865317</u> , PubMed: <u>14559847</u> , PubMed: <u>15373842</u> , PubMed: <u>15764715</u> , PubMed: <u>21490593</u> ,
	PubMed: <u>21576599</u> , PubMed: <u>2732228</u>). Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta- estradiol (E2), namely 2-hydroxy E1 and E2, as well as D-ring hydroxylated E1 and E2 at the
	C-16 position (PubMed: <u>11555828</u> , PubMed: <u>12865317</u> , PubMed: <u>14559847</u>). Plays a role in the metabolism of androgens, particularly in oxidative deactivation of testosterone (PubMed: <u>15373842</u> , PubMed: <u>15764715</u> ,
	PubMed: <u>22773874</u> , PubMed: <u>2732228</u>). Metabolizes testosterone to less
	biologically active 2beta- and 6beta- hydroxytestosterones (PubMed: <u>15373842</u> , PubMed: <u>15764715</u> , PubMed: <u>2732228</u>). Contributes to the formation of hydroxycholesterols (oxysterols), particularly A-ring hydroxylated
	cholesterol at the C- 4beta position, and side chain hydroxylated cholesterol at the C-25 position, likely contributing to cholesterol degradation and bile acid biosynthesis (PubMed: <u>21576599</u>). Catalyzes bisallylic hydroxylation of
	polyunsaturated fatty acids (PUFA) (PubMed: <u>9435160</u>). Catalyzes the epoxidation of double bonds of PUFA with a preference for the last double
	bond (PubMed: <u>19965576</u>). Metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 8,9-, 11,12-, and 14,15-
	epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling (PubMed: <u>20702771</u>). Plays a role in the
	metabolism of retinoids. Displays high catalytic activity for oxidation of all-trans-retinol to all-trans-retinal, a rate- limiting step for the biosynthesis of
	all-trans-retinoic acid (atRA) (PubMed: <u>10681376</u>). Further metabolizes atRA toward 4-hydroxyretinoate and may play a role in hepatic atRA clearance
	(PubMed: <u>11093772</u>). Responsible for oxidative metabolism of xenobiotics. Acts as a 2-exo- monooxygenase for plant lipid 1,8-cineole (eucalyptol) (PubMed: <u>11159812</u>). Metabolizes the majority of the administered drugs.
	Catalyzes sulfoxidation of the anthelmintics albendazole and fenbendazole (PubMed: <u>10759686</u>). Hydroxylates antimalarial drug quinine
	(PubMed: <u>1695850</u>). Acts as a 1,4-cineole 2-exo-monooxygenase (PubMed: <u>11695850</u>). Also involved in vitamin D catabolism and calcium
	homeostasis. Catalyzes the inactivation of the active hormone calcitriol
	(1-alpha,25-dihydroxyvitamin D(3)) (PubMed: <u>29461981</u>).
Cellular Location	Endoplasmic reticulum membrane; Single-pass membrane protein. Microsome membrane; Single-pass membrane protein
Tissue Location	Expressed in prostate and liver. According to some authors, it is not expressed in brain (PubMed:19094056). According to others, weak levels of expression are measured in some brain locations (PubMed:18545703, PubMed:19359404). Also expressed in epithelium of the small intestine and large intestine, bile duct, nasal mucosa, kidney, adrenal cortex, epithelium of the gastric mucosa with intestinal metaplasia, gallbladder, intercalated ducts
	of the pancreas, chief cells of the parathyroid and the corpus luteum of the ovary (at protein level).

Background

This gene, CYP3A4, encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome

P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by glucocorticoids and some pharmacological agents. This enzyme is involved in the metabolism of approximately half the drugs which are are used today, including acetaminophen, codeine, cyclosporin A, diazepam and erythromycin. The enzyme also metabolizes some steroids and carcinogens. This gene is part of a cluster of cytochrome P450 genes on chromosome 7q21.1. Previously another CYP3A gene, CYP3A3, was thought to exist; however, it is now thought that this sequence represents a transcript variant of CYP3A4.

References

Justenhoven, C., et al. Cancer 116(23):5358-5364(2011) Moore, C.D., et al. Biochemistry 49(41):9011-9019(2010) Jablonski, K.A., et al. Diabetes 59(10):2672-2681(2010) Hu, M., et al. Pharmacogenet. Genomics 20(10):634-637(2010) Coto, E., et al. Biochem. Biophys. Res. Commun. (2010) In press :

Images



Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.